Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of GR1501 injection in radiographic axial spondyloarthritis
ChiCTR2200060715Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of xeligekimab in axial spondyloarthritis (axSpA) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Proportion of patients achieving ASAS20. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
xeligekimab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on ChiCTR2200060715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060715.